ID   MaS-3
AC   CVCL_A8UM
DR   DSMZ; ACC-901
DR   DSMZCellDive; ACC-901
DR   Wikidata; Q108820850
RX   PubMed=33727576;
CC   Population: Caucasian.
CC   Doubling time: 26 hours (PubMed=33727576); ~60-80 hours (DSMZ=ACC-901).
CC   Karyotypic information: Hypotriploid to hypertriploid karyotype (PubMed=33727576).
CC   Omics: Deep proteome analysis.
CC   Derived from site: In situ; Kidney, renal pelvis; UBERON=UBERON_0001224.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): DSMZ=ACC-901; PubMed=33727576
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 12
ST   D16S539: 8,12
ST   D18S51: 14
ST   D19S433: 14,15
ST   D21S11: 28
ST   D2S1338: 17,25
ST   D3S1358: 16
ST   D5S818: 11,13
ST   D7S820: 8,10
ST   D8S1179: 13,14
ST   FGA: 25
ST   Penta D: 11
ST   Penta E: 7,12
ST   TH01: 7,9.3
ST   TPOX: 8,10
ST   vWA: 15,17
DI   NCIt; C39824; Infiltrating bladder urothelial carcinoma, sarcomatoid variant
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   86Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 02-05-24; Version: 7
//
RX   PubMed=33727576; DOI=10.1038/s41598-021-85400-5; PMCID=PMC7971026;
RA   Eberhard J., Hirsch D., Schilling O., Dirks W.G., Guo F., Fabarius A.,
RA   Ruckert F., Reissfelder C., Hohenberger P., Pallavi P.;
RT   "First report on establishment and characterization of a
RT   carcinosarcoma tumour cell line model of the bladder.";
RL   Sci. Rep. 11:6030-6030(2021).
//